Decitabine studies in chronic and acute myelogenous leukemia

Leukemia

Volumn 11, Issue SUPPL. 1, 1997, Pages

  Kantarjian, H M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Acute leukemia; Chronic leukemia; Decitabine; Methylation

Indexed keywords

5 AZA 2' DEOXYCYTIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; FEMALE; HUMAN; INFECTION; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; VOMITING;

EID: 0030985020     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Pinto A, Zagonel V. 5-Aza-2′-deoxycytidine (Decitabine) and 5-Azacytidine in the treatment of acute myeloid leukemias and myelodysplastic syndromes: past, present and future trends. Leukemia 1993; 7 (Suppl. 1): 51-60.
2. Petti MC, Mandelli F, Zagonel V et al. Pilot study of 5-Aza-2′-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia 1993; 7 (Suppl. 1): 36-41.